Connor Clark & Lunn Investment Management Ltd. trimmed its position in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 25.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,840 shares of the biotechnology company's stock after selling 30,652 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.17% of Prothena worth $1,272,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in the company. Orion Portfolio Solutions LLC increased its position in Prothena by 4.4% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock valued at $293,000 after purchasing an additional 739 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Prothena by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,065 shares during the period. Rhumbline Advisers increased its position in Prothena by 1.8% during the 4th quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company's stock valued at $930,000 after purchasing an additional 1,175 shares during the period. Charles Schwab Investment Management Inc. increased its position in Prothena by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 327,151 shares of the biotechnology company's stock valued at $4,531,000 after purchasing an additional 2,189 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in Prothena by 3.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company's stock valued at $1,440,000 after purchasing an additional 3,163 shares during the period. 97.08% of the stock is owned by hedge funds and other institutional investors.
Prothena Price Performance
Prothena stock traded up $0.10 during mid-day trading on Friday, reaching $12.97. The stock had a trading volume of 869,554 shares, compared to its average volume of 483,915. The company has a market capitalization of $698.14 million, a price-to-earnings ratio of -5.64 and a beta of -0.02. The company has a 50-day moving average price of $14.33 and a two-hundred day moving average price of $15.83. Prothena Co. plc has a one year low of $11.70 and a one year high of $26.36.
Prothena (NASDAQ:PRTA - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). The firm had revenue of $2.12 million during the quarter, compared to the consensus estimate of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. On average, equities research analysts anticipate that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on PRTA shares. StockNews.com raised shares of Prothena from a "sell" rating to a "hold" rating in a research report on Monday, February 24th. Oppenheimer boosted their price objective on shares of Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a research report on Friday, February 7th. Cantor Fitzgerald reissued an "overweight" rating on shares of Prothena in a research report on Friday, February 21st. Piper Sandler upped their target price on shares of Prothena from $94.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Bank of America reduced their target price on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a research report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $55.00.
Check Out Our Latest Stock Analysis on Prothena
Prothena Company Profile
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Read More
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
